Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Japan's Daiichi Sankyo will buy a majority stake in India's top drug maker in a deal that will vault the combined operations into the top 15 pharmaceutical firms globally and end the founding Singh family's role as largest shareholder of Ranbaxy Laboratories
Advertisement

Related Content

India Story Tempered? Government May Put Future Brownfield Buyouts Under Scrutiny; No Qualms On Greenfield Investments
Battling Negative Image Of Generics In Japan (Part 2 of 2)
Shionogi’s Brisk Crestor Sales Help It Buck Industry Tide Of Lower Earnings
Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition
Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition
Eisai, Takeda Report Losses Due to Acquisitions; Daiichi Sankyo Reports Earnings Lower Because Of NHI Drug Pricing
Ranbaxy Denies Fraudulent Conduct Alleged By U.S. FDA As Rumors Swirl About Daiichi Deal
Daiichi Sankyo Announces Open Offer To Ranbaxy Shareholders For Additional Stake
Analysts Say Ranbaxy Management Would Likely Rebuff Any Pfizer Offer
Analysts See Daiichi Sankyo Exercising Light Control Of Ranbaxy
Advertisement
UsernamePublicRestriction

Register

SC068663

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel